vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and SES AI Corp (SES). Click either name above to swap in a different company.
SES AI Corp is the larger business by last-quarter revenue ($4.6M vs $3.9M, roughly 1.2× Citius Pharmaceuticals, Inc.). Citius Pharmaceuticals, Inc. runs the higher net margin — -238.2% vs -373.5%, a 135.3% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
SES S.A. is a Luxembourgish communications satellite operator supplying video and data connectivity worldwide to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions.
CTXR vs SES — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.6M |
| Net Profit | $-9.4M | $-17.0M |
| Gross Margin | 80.0% | 11.3% |
| Operating Margin | -228.7% | -387.7% |
| Net Margin | -238.2% | -373.5% |
| Revenue YoY | — | — |
| Net Profit YoY | 8.6% | 50.7% |
| EPS (diluted) | $-0.38 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $4.6M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $3.5M | ||
| Q1 25 | — | $5.8M |
| Q4 25 | $-9.4M | $-17.0M | ||
| Q3 25 | — | $-20.9M | ||
| Q2 25 | — | $-22.7M | ||
| Q1 25 | — | $-12.4M |
| Q4 25 | 80.0% | 11.3% | ||
| Q3 25 | — | 51.1% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 78.7% |
| Q4 25 | -228.7% | -387.7% | ||
| Q3 25 | — | -262.0% | ||
| Q2 25 | — | -652.3% | ||
| Q1 25 | — | -401.7% |
| Q4 25 | -238.2% | -373.5% | ||
| Q3 25 | — | -293.9% | ||
| Q2 25 | — | -642.2% | ||
| Q1 25 | — | -214.6% |
| Q4 25 | $-0.38 | $-0.05 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | — | $-0.07 | ||
| Q1 25 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $29.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $214.8M |
| Total Assets | $140.4M | $272.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $29.5M | ||
| Q3 25 | — | $35.3M | ||
| Q2 25 | — | $11.8M | ||
| Q1 25 | — | $56.1M |
| Q4 25 | $80.0M | $214.8M | ||
| Q3 25 | — | $228.2M | ||
| Q2 25 | — | $249.2M | ||
| Q1 25 | — | $269.9M |
| Q4 25 | $140.4M | $272.6M | ||
| Q3 25 | — | $288.8M | ||
| Q2 25 | — | $290.5M | ||
| Q1 25 | — | $306.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-10.4M |
| Free Cash FlowOCF − Capex | — | $-11.1M |
| FCF MarginFCF / Revenue | — | -243.7% |
| Capex IntensityCapex / Revenue | — | 15.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-61.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $-10.4M | ||
| Q3 25 | — | $-14.3M | ||
| Q2 25 | — | $-10.8M | ||
| Q1 25 | — | $-22.8M |
| Q4 25 | — | $-11.1M | ||
| Q3 25 | — | $-14.7M | ||
| Q2 25 | — | $-11.6M | ||
| Q1 25 | — | $-23.7M |
| Q4 25 | — | -243.7% | ||
| Q3 25 | — | -206.9% | ||
| Q2 25 | — | -329.6% | ||
| Q1 25 | — | -410.0% |
| Q4 25 | — | 15.6% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 22.8% | ||
| Q1 25 | — | 15.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
